FamiCord AG (VTIAF)
- Previous Close
6.28 - Open
4.52 - Bid 4.21 x 45100
- Ask 5.21 x --
- Day's Range
4.52 - 4.52 - 52 Week Range
4.52 - 5.99 - Volume
101 - Avg. Volume
0 - Market Cap (intraday)
104.416M - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
-- - EPS (TTM)
-1.67 - Earnings Date Apr 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the company provides biobanking services, such as freezing sperm and storage of adipose tissue and the isolation of cells from the stored materials. The company was formerly known as VITA 34 AG and changed its name to FamiCord AG in February 2025. FamiCord AG was founded in 1997 and is based in Leipzig, Germany.
www.famicord.com783
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: VTIAF
View MorePerformance Overview: VTIAF
Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VTIAF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VTIAF
View MoreValuation Measures
Market Cap
80.95M
Enterprise Value
82.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
3.20%
Return on Assets (ttm)
-0.20%
Return on Equity (ttm)
14.85%
Revenue (ttm)
80.64M
Net Income Avi to Common (ttm)
2.58M
Diluted EPS (ttm)
-1.67
Balance Sheet and Cash Flow
Total Cash (mrq)
17.63M
Total Debt/Equity (mrq)
80.30%
Levered Free Cash Flow (ttm)
16.26M